LLM-based platform for generating new materials synthesis recipes dramatically cuts trial and error
A research team led by Professor Sung Beom Cho of Sungkyunkwan University (SKKU) in South Korea, in collaboration with Ajou University and MIT, has developed a closed-loop materials synthesis planning platform. This platform uses a large language model (LLM) to propose synthesis conditions for new materials and refines them based on experimental results. The team built a database from 4,407 open-access solid-state synthesis papers, applying a retrieval-augmented generation (RAG) method to suggest recipes. This approach successfully synthesized a single-phase new material for all-solid-state batteries within a few experiments, significantly reducing trial and error in materials design.
South Korean universities SKKU and Ajou, alongside MIT, have demonstrated a practical application of LLMs in materials science. Their platform, which leverages a database of 4,407 synthesis papers, uses AI to propose and refine recipes for new materials. This iterative process, where experimental feedback informs the LLM, cut down the trial and error for synthesizing an oxy-selenide-based solid electrolyte material for all-solid-state batteries. The initial AI-proposed 600°C condition led to impurities, but subsequent AI-guided adjustments to 450°C and 400°C quickly yielded a pure material. This shows how AI can accelerate R&D by integrating vast literature with real-world experimental outcomes. The immediate impact for Asia is in advanced manufacturing and battery technology, particularly for nations like South Korea and Japan that are heavily invested in these sectors. Reducing development timelines for new materials directly translates to faster innovation cycles and potential competitive advantages in critical industries. The methodology suggests a future where AI-assisted scientific discovery becomes standard, potentially lowering the barrier to entry for complex materials research and development across the region.
分享這篇文章
相關文章
6 則
Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth
Viva Biotech's interim results highlight AI's transformative role in drug R&D, mirroring this story's theme of AI accelerating scientific discovery.

美國抑或中國?哈薩克發展人工智能拒絕選邊站

LUXEED 與 Aimoga 機器人:透過互聯的人車家生態系統共同建構未來出行

馬來西亞希望擺脫Waze。司機們會轉用嗎?

Stripe 發票不等於收入:如何透過網絡掛鈎將其轉化為 ASC 606 附表

